Granted Patent
B2
US 12,268,901 · App. 17/933,709 · Granted Apr 8, 2025
Targeting cell tropism receptors to inhibit cytomegalovirus infection
Inventors:
Timothy F. Kowalik (Princeton, MA); Xiaofei E (Westborough, MA); Abraham L Brass (Newton, MA)
Assignee:
University of Massachusetts
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.
Claims (5)
1. A composition comprising an inhibitor of Olfactory Receptor Family 14 Subfamily 1 Member 1 (OR14I1), wherein the inhibitor of OR14I1 is a N-terminal peptide of OR14I1 comprising the amino acid sequence MDNLTKVTEFLLMEFSGIWELQVLHA (SEQ ID NO:1), or an active fragment thereof, and a pharmaceutically acceptable carrier.
2. The composition of claim 1 , wherein the active fragment comprises FLLMEFSGIWELQ (SEQ ID NO:3), LLMEFSGIWELQV (SEQ ID NO:4), LMEFSGIWELQVL (SEQ ID NO:5), or LMEFSGIWELQ (SEQ ID NO:6).
3. The composition of claim 1 , further comprising an inhibitor of adenylyl cyclases selected from the group consisting of 9-Cyclopentyladenine monomethanesulfonate; 2′,5′-Dideoxyadenosine; 2′,5′-Dideoxyadenosine 3′-triphosphate tetrasodium salt; Dihomo-gamma-linolenylethanolamide; KH7; LRE1; MDL-12330A; NKY80; SB-268262; BPIPP; SKF 83566; and SQ 22,536.
4. The composition of claim 1 , wherein the peptide is modified.
5. The composition of claim 4 , wherein the modified peptide comprises one or more D amino acids, artificial amino acids analogs, or a lipophilic substituent linked to an amino acid.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 15, 2023
From: KOWALIK, TIMOTHY F.; E, XIAOFEI; BRASS, ABRAHAM L.
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 062986/0484 →
Continuity (3)
Division
16604735
Provisional Application
62485742
· Apr 14, 2017
References Cited (44)
US 20040248839A1
· Kowalik
· 2004
[cited by applicant]
US 20070009916A1
· Suwa et al.
· 2007
[cited by applicant]
US 20130323835A1
· McDonald et al.
· 2013
[cited by applicant]
WO WO199601107
· 1996
[cited by applicant]
WO WO2004071430
· 2004
[cited by applicant]
WO WO2010007533
· 2010
[cited by applicant]
WO WO2014071430
· 2014
[cited by applicant]
WO WO2016030378
· 2016
[cited by applicant]
Adler et al., “Role of human cytomegalovirus UL131A in cell type-specific virus entry and release,” Journal of General Virology, Sep. 1, 2006, 87(9):2451-60.
[cited by applicant]
Chiuppesi et al., “Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection,” Journal of Virology, Dec. 1, 2015, 89(23):11884-98.
[cited by applicant]
Demmler, “Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease,” Reviews of Infectious Diseases, Mar. 1, 1991, 13(2):315-29.
[cited by applicant]
E et al., “A novel DDB2-ATM feedback loop regulates human cytomegalovirus replication,” Journal of virology, Feb. 15, 2014, 88(4):2279-90.
[cited by applicant]
E et al., “An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus,” PLoS Pathogens, May 12, 2011, 7(5):e1001342, 11 pages.
[cited by applicant]
EP Extended Search Report in European AppIn. No. 18784005.3, dated May 14, 2021, 7 pages.
[cited by applicant]
EP Supplementary European Search Report in European Appln. No. 18784005.3, dated Feb. 11, 2021, 14 pages.
[cited by applicant]
Gault et al., “Quantification of human cytomegalovirus DNA by real-time PCR,” Journal of Clinical Microbiology, Feb. 1, 2001, 39(2):772-5.
[cited by applicant]
Hanfler et al., “Quantitation of cytomegalovirus (hCMV) DNA and beta-actin DNA by duplex real-time fluorescence PCR in solid organ (liver) transplant recipients,” Medical Microbiology and Immunology, Nov. 2003, 192:197-…
[cited by applicant]
Intemational Search Report and Written Opinion in International Appln. No. PCT/US2018/027469, dated Jul. 24, 2018, 14 pages.
[cited by applicant]
Istas et al., “Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry,” Clinical Infectious Diseases, Mar. 1, 1995, 20(3):665-70.
[cited by applicant]
Kim et al., “Viral binding-induced signaling drives a unique and extended intracellular trafficking pattern during infection of primary monocytes,” Proceedings of the National Academy of Sciences, Aug. 2, 2016, 113(31):…
[cited by applicant]
Lee et al. “US28, a Virally-Encoded GPCR as an Antiviral Target for Human Cytomegalovirus Infection,” Biomol Ther, Jan. 1, 2017 {Jan. 1, 2017), vol. 25, No. 1. pp. 69-79.
[cited by applicant]
Malinger et al., “Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings,” American Journal of Neuroradiology, Jan. 1, 2003, 24(1):28-32.
[cited by applicant]
Merigan, “Treatment of AIDS with combinations of antiretroviral agents,” The American Journal of Medicine, Apr. 10, 1991, 90(4):S8-17.
[cited by applicant]
Miazzi et al., “Odor-induced cAMP production in
[cited by applicant]
Paredes et al., “Human cytomegalovirus: bacterial artificial chromosome (BAC) cloning and genetic manipulation,” Current Protocols in Microbiology, Feb. 2012, 24(1):14E-4, 33 pages.
[cited by applicant]
Perreira et al., “Functional genomic strategies for elucidating human-virus interactions: will CRISPR knockout RNAi and haploid cells?, ”Advances in Virus Research, Jan. 1, 2016, 1;94:1-51.
[cited by applicant]
Pinto et al., “Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs,” Journal of Pharmacology and Experimental Therapeutics, Apr. 1, 2008, 325(1):27-36.
[cited by applicant]
Ryckman et al., “HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors,” Proceedings of the National Academy of Sciences, Sep. 16, 2008, 105(37):14118-23.
[cited by applicant]
Ryckman et al., “Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion,” Journal of Virology, Jan. 15, 2006, 80(2):710-22.
[cited by applicant]
Savidis et al. “Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics,” Cell Reports, Jun. 28, 2016 (Jun. 28, 2016), vol. 16, pp. 232-246.
[cited by applicant]
Shalem et al., “Genome-scale CRISPR-Cas9 knockout screening in human cells,” Science, Jan. 3, 2014, 343(6166):84-7.
[cited by applicant]
Shih et al., “Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors,” Proceedings of the National Academy of Sciences, Nov. 1, 1991, 8…
[cited by applicant]
Tao et al., “Frizzled proteins are colonic epithelial receptors for C. difficile toxin B.” Nature, Oct. 20, 2016, 538(7625):350-5.
[cited by applicant]
Wang et al., “Delivery of Cas9 protein into mouse zygotes through a series of electroporation dramatically increases the efficiency of model creation,” Journal of Genetics and Genomics. May 20, 2016, 43(5):319-27.
[cited by applicant]
Wang et al., “Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism,” Journal of Virology, Aug. 15, 2005, 79(16):10330-8.
[cited by applicant]
Wang et al., “Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism,” Proceedings of the National Academy of Sciences, Dec. 13, 2005, 102(50):18153-8.
[cited by applicant]
White et al., “A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates,” Antiviral Research, Oct. 1, 1991, 16(3):257-66.
[cited by applicant]
Xiaofei E et al., OR1411 is a receptor for the human cytomegalovirus pentanneric complex and defines viral epithelial cell tropism. Proc Natl Acad Sci USA 116(14):7043-7052, 2019.
[cited by applicant]
Yu et al., “Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene,” Journal of Virology, Mar. 1, 2002, 76(5):2316-28.
[cited by applicant]
EP Office Action in European Appln. No. 18784005.3, mailed on Aug. 29, 2023, 8 pages.
[cited by applicant]